EUVIMEDEUVIMED entdecken
Crossref

Standardization of definition and management for bleeding disorder of unknown cause: communication from the SSC of the ISTH

Ross I Baker, Philip Choi, Nicola Curry, Johanna Gebhart, Keith Gomez, Yvonne Henskens, Floor Heubel-Moenen, Paula James, Rezan Abdul Kadir, Peter Kouides, Michelle Lavin, Marie Lordkipanidze und 10 weitere

Journal of Thrombosis and Haemostasis · 2024-07 · 22 (7) · 2059-2070

DOI: 10.1016/j.jtha.2024.03.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024-07. Verfasst von Ross I Baker und 21 weiteren Autor:innen. Beteiligte Einrichtung: Western Australia Centre for Thrombosis and Haemostasis, Murdoch University, Perth, Australia; Clinical Research Unit, Perth Blood Institute, Perth, …. Hauptthemen laut MEDLINE: Hemostasis. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 76 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In many patients referred with significant bleeding phenotype, laboratory testing fails to define any hemostatic abnormalities. Clinical practice with respect to diagnosis and management of this patient cohort poses significant clinical challenges. We recommend that bleeding history in these patients should be objectively assessed using the International Society on Thrombosis and Haemostasis (ISTH) bleeding assessment tool. Patients with increased bleeding assessment tool scores should progress to hemostasis laboratory testing. To diagnose bleeding disorder of unknown cause (BDUC), normal complete blood count, prothrombin time, activated partial thromboplastin time, thrombin time, von Willebrand factor antigen, von Willebrand factor function, coagulation factors VIII, IX, and XI, and platelet light transmission aggregometry should be the minimum laboratory assessment. In some laboratories, additional specialized hemostasis testing may be performed to identify other rare causes of bleeding. We recommend that patients with a significant bleeding phenotype but normal laboratory investigations should be registered with a diagnosis of BDUC in preference to other terminology. Global hemostatic tests and markers of fibrinolysis demonstrate variable abnormalities, and their clinical significance remains uncertain. Targeted genomic sequencing examining candidate hemostatic genes has a low diagnostic yield. Underlying BDUC should be considered in patients with heavy menstrual bleeding since delays in diagnosis often extend to many years and negatively impact quality of life. Treatment options for BDUC patients include tranexamic acid, desmopressin, and platelet transfusions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HemostasisHumansBlood CoagulationBlood Coagulation TestsHemorrhageHemorrhagic DisordersPhenotypePractice Guidelines as TopicPredictive Value of TestsTerminology as Topic

Stichwörter der Autor:innen

heavy menstrual bleedinghemostaticplatelet function teststranexamic acidvon Willebrand disease

Autor:innen und Institutionen

  • Western Australia Centre for Thrombosis and Haemostasis, Murdoch University, Perth, Australia; Clinical Research Unit, Perth Blood Institute, Perth, Australia; Hollywood Hospital Haemophilia Centre, Haematology Academic…
  • Haematology Department, The Canberra Hospital, Canberra, Australia; Division of Genome Sciences and Cancer, John Curtin School of Medical Research, Australian National University, Canberra, Australia.
  • Department of Clinical Haematology, Haemophilia & Thrombosis Centre, Oxford University Hospitals National Health Service Foundation Trust, Oxford, United Kingdom; Radcliffe Department of Medicine, Oxford University, Oxf…
  • Department of Medicine, Division of Hematology and Hemostaseology, Medical University Vienna, Vienna, Austria.
  • Katharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free London National Health Service Foundation Trust, London, United Kingdom.
  • Central Diagnostic Laboratory, Maastricht University Medical Centre, Maastricht, The Netherlands; Department of Biochemistry, Institute for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands.

Zitieren

APA

Baker, R. I., Choi, P., Curry, N., Gebhart, J., Gomez, K., Henskens, Y., Heubel-Moenen, F., James, P., Kadir, R. A., Kouides, P., Lavin, M., Lordkipanidze, M., Lowe, G., Mumford, A., Mutch, N., Nagler, M., Othman, M., Pabinger, I., Sidonio, R., …, & ISTH SSC Von Willebrand Factor, Platelet Physiology, and Women’s Health Issues in Thrombosis and Haemostasis (2024). Standardization of definition and management for bleeding disorder of unknown cause: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 22(7), 2059-2070. https://doi.org/10.1016/j.jtha.2024.03.005

Vancouver

Baker RI, Choi P, Curry N, Gebhart J, Gomez K, Henskens Y, et al. Standardization of definition and management for bleeding disorder of unknown cause: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 2024;22(7):2059-2070. doi:10.1016/j.jtha.2024.03.005

BibTeX
@article{Baker2024,
  author = {Baker, Ross I and Choi, Philip and Curry, Nicola and Gebhart, Johanna and Gomez, Keith and Henskens, Yvonne and Heubel-Moenen, Floor and James, Paula and Kadir, Rezan Abdul and Kouides, Peter and Lavin, Michelle and Lordkipanidze, Marie and Lowe, Gillian and Mumford, Andrew and Mutch, Nicola and Nagler, Michael and Othman, Maha and Pabinger, Ingrid and Sidonio, Robert and Thomas, Will and O'Donnell, James S and ISTH SSC Von Willebrand Factor, Platelet Physiology, and Women’s Health Issues in Thrombosis and Haemostasis, ISTH SSC Von Willebrand Factor, Platelet Physiology, and Women’s Health Issues in Thrombosis and Haemostasis},
  title = {Standardization of definition and management for bleeding disorder of unknown cause: communication from the SSC of the ISTH},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2024},
  volume = {22},
  number = {7},
  pages = {2059--2070},
  doi = {10.1016/j.jtha.2024.03.005}
}
Kostenlos starten →